Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,237 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Disorder Clear all
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Pharmacological Modulation of Brain Oscillations in Memory Processing

NCT05594017
View directory record Official record
Conditions
Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders, Memory Loss
Interventions
Scopolamine (0.4mg), Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome

NCT07531745
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ION337
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 12 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Completed No phase listed Observational

Detecting Absence Seizures Using Eye Tracking

NCT04439656
View directory record Official record
Conditions
Epilepsy, Generalized, Absence Epilepsy, Absence Seizures, Seizures, Seizure Disorder
Interventions
Eye movement analysis
Diagnostic Test
Lead sponsor
Rachel Kuperman
Industry
Eligibility
4 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Orange, California • San Diego, California • San Francisco, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 26, 2026, 5:28 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 26, 2026, 5:28 AM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures

NCT00655486
View directory record Official record
Conditions
Partial Epilepsies, Partial Onset Seizures
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 60 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Phoenix, Arizona • Baltimore, Maryland • Chesterfield, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 26, 2026, 5:28 AM EDT
Completed No phase listed Observational

Neural Correlates of Cognition and Mood

NCT04573569
View directory record Official record
Conditions
Epilepsy, Complex Partial
Interventions
Behavioral testing
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

NCT00448916
View directory record Official record
Conditions
Epilepsies, Partial
Interventions
Pregabalin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Month to 16 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Not applicable Interventional Results available

Microelectrodes in Epilepsy

NCT05200455
View directory record Official record
Conditions
Epilepsy
Interventions
Microelectrodes
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 26, 2026, 5:28 AM EDT
Recruiting Phase 3 Interventional

Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))

NCT05135091
View directory record Official record
Conditions
Mesial Temporal Lobe Epilepsy
Interventions
NRTX-1001, Sham Comparator
Biological · Procedure
Lead sponsor
Neurona Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2043
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Epilepsy Database

NCT00204360
View directory record Official record
Conditions
Epilepsy
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 17 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome

NCT06118255
View directory record Official record
Conditions
Dravet Syndrome
Interventions
fenfluramine
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
1 Year to 23 Months
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Memphis, Tennessee • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Recruiting Phase 2 Interventional

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

NCT05851391
View directory record Official record
Conditions
Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus, Seizures, Anoxic-Ischemic Encephalopathy, Anoxia-Ischemia, Cerebral
Interventions
Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome

NCT02332655
View directory record Official record
Conditions
Sturge-Weber Syndrome
Interventions
Cannabidiol
Drug
Lead sponsor
Anne Comi, MD
Other
Eligibility
1 Month to 45 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 26, 2026, 5:28 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

NCT05787587
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
Interventions
IDE-161, Pembrolizumab
Drug
Lead sponsor
IDEAYA Biosciences
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Terminated Phase 4 Interventional Results available

Seizure Prophylaxis in Aneurysm Repair

NCT01974700
View directory record Official record
Conditions
Intracranial Aneurysms, Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 26, 2026, 5:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Childhood Absence Epilepsy Rx PK-PD-Pharmacogenetics Study

NCT00088452
View directory record Official record
Conditions
Childhood Absence Epilepsy, Petit Mal Epilepsy, Epilepsy, Seizures
Interventions
Ethosuximide, Lamotrigine, Valproic acid
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
30 Months to 13 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2016
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 26, 2026, 5:28 AM EDT
Recruiting Phase 4 Interventional

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

NCT06598449
View directory record Official record
Conditions
Dravet Syndrome (DS), Children Under 2 Years
Interventions
fenfluramine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Months to 24 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 26, 2026, 5:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Taurine Therapy for SSADH Deficiency

NCT01608178
View directory record Official record
Conditions
Succinic Semialdehyde Dehydrogenase
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 26, 2026, 5:28 AM EDT
Withdrawn Phase 2 Interventional

Trial Investigating the Safety and Efficacy of BRC-003 in Refractory Post-Traumatic Epilepsy

NCT06523725
View directory record Official record
Conditions
Post-traumatic Epilepsy
Interventions
PO BRC-003 (High Cannabidiol Cannabis Extract), Placebo
Drug
Lead sponsor
Dr. Paul Lyons
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 26, 2026, 5:28 AM EDT
Completed No phase listed Observational

Monitoring Patients With Uncontrolled Epilepsy

NCT00001149
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1975 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 26, 2026, 5:28 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Dentatorubral-pallidoluysian Atrophy Natural History and Biomarkers Study

NCT06273150
View directory record Official record
Conditions
Dentatorubral-Pallidoluysian Atrophy
Interventions
Positive genetic test for pathological expansion in ATN1
Other
Lead sponsor
University College, London
Other
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 26, 2026, 5:28 AM EDT
Available No phase listed Expanded access

Intermediate-Size Expanded Access Protocol (EAP) for LP352

NCT06149663
View directory record Official record
Conditions
Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
Interventions
LP352
Drug
Lead sponsor
Longboard Pharmaceuticals
Industry
Eligibility
2 Years to 65 Years
U.S. locations
19
States / cities
Downey, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Oct 26, 2026, 5:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy

NCT02815540
View directory record Official record
Conditions
Lennox-Gastaut Syndrome, Dravet Syndrome
Interventions
12-Lead ECG, Cannabidiol
Procedure · Drug
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
2 Years to 30 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 26, 2026, 5:28 AM EDT